Blog
RSS FeedPosted by Michael Wonder on 31 Jan 2025
Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR positive, HER2 negative breast cancer
31 January 2025 - Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan reduced risk of disease ...
Posted by Michael Wonder on 31 Jan 2025
Highlights from the 27-30 January 2025 CHMP meeting
31 January 2025 - Eight new medicines recommended for approval; one positive opinion for a medicine intended for use outside the ...
Posted by Michael Wonder on 31 Jan 2025
Outcomes from the December 2024 PBAC meeting
31 January 2025 - Recommendations made by the PBAC in December 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 31 Jan 2025
Rystiggo (rozanolixizumab) for generalised myasthenia gravis receives EU approval for two new administration methods
31 January 2025 - Rystiggo can now be self-administered, or administered by a caregiver, with an infusion pump or manual push ...
Posted by Michael Wonder on 31 Jan 2025
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
30 January 2025 - We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life. ...
Posted by Michael Wonder on 29 Jan 2025
Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC
16 January 2025 - The rare muscle wasting disorder affects approximately 2,500 males in the UK at any one time. ...
Posted by Michael Wonder on 29 Jan 2025
EMA publishes agenda for 27-30 January 2025 CHMP meeting
27 January 2025 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 28 Jan 2025
Spesolimab for the treatment of patients with generalised pustular psoriasis flares
24 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jan 2025
Harnessing expertise to improve patient access to innovative health technologies
28 January 2025 - Introducing the Medicines and Medical Devices Access Initiative: a new collaboration that aims to improve patient access ...
Posted by Michael Wonder on 28 Jan 2025
January 2025 decisions
13 January 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 28 Jan 2025
Tarlatamab for previously treated patients with advanced small-cell lung cancer
28 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 23 Jan 2025
Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...
Posted by Michael Wonder on 22 Jan 2025
Abiraterone acetate with niraparib tosylate monohydrate and prednisone for untreated hormone-relapsed metastatic prostate cancer
22 January 2025 - NICE is unable to make a recommendation on the use in the NHS of abiraterone acetate with ...
Posted by Michael Wonder on 21 Jan 2025
NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...